| Literature DB >> 8200213 |
A Jordan1.
Abstract
Depo-Provera (depot-medroxyprogesterone acetate or DMPA), administered either subcutaneously or intramuscularly, has undergone a thorough toxicological evaluation in a number of animal species. DMPA has been tested in short- and long-term toxicity studies in rodents, rabbits, and monkeys. It has been examined for its effects on reproduction in mice, rats, and rabbits, and for carcinogenic potential in rats, mice, beagle dogs, and rhesus monkeys. Genotoxicity tests have been performed in vitro and in vivo. This paper describes the toxicology data submitted to the US FDA in support of the New Drug Application (NDA) for Depo-Provera as well as data published in the literature. When interpreted in the light of the available pharmacokinetic information, these data demonstrate that DMPA is not significantly different from other contraceptive progestogens in its toxic and tumorigenic potential.Entities:
Keywords: Americas; Animals, Laboratory; Biology; Clinical Research; Contraception; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--side effects; Depo-provera--side effects; Developed Countries; Evaluation; Family Planning; Knowledge; Measurement; Medroxyprogesterone Acetate--side effects; North America; Northern America; Physiology; Product Approval; Research Methodology; Research Report; Risk Assessment; Testing; Toxicity; United States
Mesh:
Substances:
Year: 1994 PMID: 8200213 DOI: 10.1016/0010-7824(94)90037-x
Source DB: PubMed Journal: Contraception ISSN: 0010-7824 Impact factor: 3.375